glp-1 kidney outcomes news Human, exendin-based receptor agonists similarly reduce CV, renal risk in diabetes Select Kidney Outcomes from GLP-1

Nonhematological mechanisms of improved sea-level performance after hypoxic exposure

Tseng, A

10.1309/AJCPGPMAF7SFRBO4 24 DhayatN

Early Phase Possible appetite or fullness changes Digestive adjustment Possible nausea or bloating Response varies by dose and individual tolerance First Few Weeks Some patients may notice appetite changes Eating patterns may begin to shift Energy and blood sugar response may vary Digestive adjustment may continue Provider follow-up helps guide next steps Ongoing Early Treatment Some patients may begin noticing weight-related changes Portion sizes may change Appetite patterns may continue adjusting Side effects may improve or require provider guidance Progress depends on the individual treatment plan Continued Provider Monitoring Provider reviews response and tolerance Weight-related progress may vary Appetite patterns may continue changing Lifestyle habits may support progress Dose or care plan may be adjusted if appropriate Longer-Term Follow-Up Ongoing progress varies by patient Provider may review labs, tolerance, and treatment response Lifestyle habits may support long-term weight management Treatment may continue, change, or stop based on clinical review What Affects How Fast You See Results

Melanotan I vs II: Understanding the Basics Melanotan I (afamelanotide) and Melanotan II are both synthetic analogues of alpha-melanocyte-stimulating hormone (MSH), but they diverged early in development

Economists preparing recommendations to the White House on allocating funds towards different COVID-19 vaccine methodologies received feedback from some corners that investment plans positing a possible role for mRNA were fanciful. - Tim Hwang at IFP Despite the very real possibility that mRNA vaccines might not work, the magnitude of COVIDs threat was enough that Operation Warp Speed invested heavily to fund and rapidly accelerate large-scale testing and deployment